Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin’s Potential to Modify Disease Progression in Advanced MASH Cirrhosis
Go back to Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin’s Potential to Modify Disease Progression in Advanced MASH Cirrhosis| GALECTIN (NASDAQ: GALT) | Delayed: 2.82 -0.01 (0.35%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.83 | 52 Week High | $3.05 | |||
| Open | $2.82 | 52 Week Low | $0.49 | |||
| Day High | $2.99 | P/E | N/A | |||
| Day Low | $2.78 | EPS | $-1.32 | |||
| Volume | 220,470 | |||||
